Tigloylgomisin P Inhibits Endothelial Inflammation by Regulating the NF-κB and Smad1/5/9 Pathways.

Area of Science:

• Biomedical Science
• Molecular Biology
• Cardiovascular Research

Background:

• Vascular inflammation is a key driver of chronic diseases like atherosclerosis.
• Endothelial activation by inflammatory stimuli (e.g., IL-1β) or disturbed blood flow promotes leukocyte recruitment.
• Targeting endothelial inflammation is crucial for developing therapies for vascular diseases.

Purpose of the Study:

• To identify novel compounds that inhibit endothelial inflammation.
• To evaluate the anti-inflammatory potential of tigloylgomisin P in preclinical models.
• To investigate the molecular mechanisms underlying tigloylgomisin P's effects on vascular inflammation.

Main Methods:

• Screening of a natural compound library to identify inhibitors of IL-1β-induced endothelial inflammation.
• Assessing tigloylgomisin P's effects on NF-κB phosphorylation, monocyte adhesion, and Smad1/5/9 phosphorylation in vitro.
• Evaluating tigloylgomisin P's efficacy in reducing vascular inflammation in ApoE knockout mice.

Main Results:

• Tigloylgomisin P suppressed IL-1β-induced NF-κB activation and reduced monocyte adhesion.
• The compound inhibited oscillatory shear stress-induced endothelial inflammation via NF-κB and Smad1/5/9 pathways.
• In vivo studies showed decreased inflammatory markers in the aortas of tigloylgomisin P-treated ApoE knockout mice.

Conclusions:

• Tigloylgomisin P demonstrates significant anti-inflammatory properties in endothelial cells and in vivo.
• The compound effectively targets key pathways involved in vascular inflammation.
• Tigloylgomisin P shows potential as a therapeutic agent for atherosclerosis and related vascular inflammatory conditions.